
An announcement from Ibio ( ($IBIO) ) is now available. On November 16, 2026, iBio reported extended preclinical data for IBIO-610, its long-acting Activin E-targeting antibody, from an obese non-human
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IBIO | Ibio | 0.73 | -0.40 | -35.82% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.73 | -35.82% |

An announcement from Ibio ( ($IBIO) ) is now available. On November 16, 2026, iBio reported extended preclinical data for IBIO-610, its long-acting Activin E-targeting antibody, from an obese non-human

iBio (IBIO) announced extended preclinical data from a non-human primate, or NHP, study of IBIO-610, potentially a first-in-class Activin E antibody candidate, presented at ObesityWeek 2026, as well as preclinical

Reports Q1 revenue $1M, consensus $16.67k. “This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity

Meeting to be held in Boston on November 11 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

Ibio ( ($IBIO) ) just unveiled an announcement. iBio, Inc. is a biotechnology company focused on developing therapeutics and vaccines using its proprietary technology platforms. The company operates in the

Ibio ( ($IBIO) ) has issued an announcement. On Oct. 13, 2026, iBio reported preclinical body-composition data from an eight-week obese non-human primate study of IBIO-610, a potentially first-in-class Activin

iBio (IBIO) highlighted preclinical body-composition data from its obese non-human primate, or NHP, study evaluating IBIO-610, alone and in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity.

Analyst Ananda Ghosh of H.C. Wainwright maintained a Buy rating on Ibio, retaining the price target of $7.00. Ananda Ghosh has given his Buy rating due to a combination of

H.C. Wainwright initiated coverage of iBio (IBIO) with a Buy rating and $7 price target The firm believes IBIO-610’s activin E antibody “looks promising.” The drug addressesa next-generation obesity, type

An announcement from Ibio ( ($IBIO) ) is now available. In September 2026, iBio updated its corporate presentation to highlight a strategic focus on “breakthrough antibodies” for obesity and cardiometabolic
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 16, 2027TBA | $49.79M | $-0.08 | $0.00 | 0.07 | -2.56 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.